Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors.
BACKGROUND
Borderline ovarian tumors often affect women of childbearing age and the prognosis is outstanding. Given the young age of several patients and the good prognosis, fertility-sparing surgery is considered adequate for stage I tumors. However, women treated conservatively have a relatively small but well-defined risk of recurrence and no study has specifically addressed the optimal follow-up technique.


METHODS
From 1981 to 1997, 164 women underwent fertility-sparing surgery for stage I borderline ovarian tumor and were followed prospectively. After surgery all women underwent physical examination and ultrasound examination every 3 months for 2 years after first diagnosis and every 6 months thereafter. Measurement of serum CA 125 levels was planned every 6 months in patients with a serous tumor.


RESULTS
With a median follow-up of 71, months 28 women treated with fertility-sparing surgery (28/164 = 17%) had either recurrence of borderline tumor (23) or recurrence with carcinoma. Complete details of follow-up procedures are available for 24 women and they represent the study population. An abnormal adnexal mass was detected in 18 of 19 women with recurrent borderline tumor. One patient had diagnosis due to persistent free fluid. All five women with invasive carcinoma had diagnosis of a complex adnexal mass. Gynecologic examination was suspicious (palpable mass) in 7 cases and obviously abnormal (large mass or nodules) in another 7. CA 125 serum levels were elevated in 8 cases.


CONCLUSIONS
Transvaginal ultrasound is currently the most effective diagnostic technique for the follow-up of young patients treated conservatively for early borderline ovarian tumor.
Department of Obstetrics and Gynecology, San Gerardo Hospital, Monza, Italy. gzanetta@iol.it
G
G
Zanetta
S
S
Rota
A
A
Lissoni
A
A
Meni
G
G
Brancatelli
A
A
Buda
D002288:Adenocarcinoma, Mucinous / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000276:immunology / Q000601:surgery; D000293:Adolescent; D000328:Adult; D018394:CA-125 Antigen / Q000097:blood*; D002648:Child; D018284:Cystadenocarcinoma, Serous / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000276:immunology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000276:immunology / Q000601:surgery; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000276:immunology / Q000601:surgery; D010808:Physical Examination; D011446:Prospective Studies; D016879:Salvage Therapy; D014463:Ultrasonography
D018394:CA-125 Antigen